MedCity News October 1, 2023
Frank Vinluan

Avalyn Pharma aims to improve treatment of Idiopathic pulmonary fibrosis with inhalable versions of two older oral drugs and it’s now headed for mid-stage testing backed by a Series C financing. Other recent biotech industry financings raised money for research in cancer, immunology, and rare genetic diseases.

The lung disease Idiopathic pulmonary fibrosis (IPF) has few available treatments, and that medical need has drawn research interest from big pharmaceutical companies and smaller biotechs. Avalyn Pharma’s approach is a new twist on two older drugs and it has raised $175 million for clinical testing.

In IPF, scar tissue called fibrosis forms in the lungs. The chronic disorder leads to worsening breathing problems that become fatal within three to five years of...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Clinical Trials, Investments, Pharma, Pharma / Biotech, Trends
The State Of CRISPR Clinical Trials And Their Future Potentials
‘Last roll of the dice’ for a near-term HIV vaccine fails
Signal: FDA renews Syapse collaboration to use real-world data in oncology
Neurostim improves cognition years after brain injury: study
Reviving Minds: Implant Restores Cognitive Functions After Brain Injury

Share This Article